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Abstract
Background: The World Health Organization guidelines have recommended that all cases of suspected malaria
should receive a confirmatory test with microscopy or a malaria rapid diagnostic test (RDT), however evidence from
sub-Saharan Africa (SSA) illustrates that only one-third of children under five with a recent fever received a test. The
aim of this study was to evaluate availability, price and market share of microscopy and RDT from 2009/11 to 2014/15
in 8 SSA countries, to better understand barriers to improving access to malaria confirmatory testing in the public and
private health sectors.
Results: Repeated national cross-sectional quantitative surveys were conducted among a sample of outlets stocking anti-malarial medicines and/or diagnostics. In total, 169,655 outlets were screened. Availability of malaria blood
testing among all screened public health facilities increased significantly between the first survey wave in 2009/11
and the most recent in 2014/15 in Benin (36.2, 85.4%, p < 0.001), Kenya (53.8, 93.0%, p < 0.001), mainland Tanzania
(46.9, 89.9%, p < 0.001), Nigeria (28.5, 86.2%, p < 0.001), Katanga, the Democratic Republic of the Congo (DRC) (76.0,
88.2%, p < 0.05), and Uganda (38.9, 95.6%, p < 0.001). These findings were attributed to an increase in availability of
RDTs. Diagnostic availability remained high in Kinshasa (the DRC) (87.6, 97.6%) and Zambia (87.9, 91.6%). Testing availability in public health facilities significantly decreased in Madagascar (88.1, 73.1%, p < 0.01). In the most recent survey
round, the majority of malaria testing was performed in the public sector in Zambia (90.9%), Benin (90.3%), Madagascar (84.5%), Katanga (74.3%), mainland Tanzania (73.5%), Uganda (71.8%), Nigeria (68.4%), Kenya (53.2%) and Kinshasa
(51.9%). In the anti-malarial stocking private sector, significant increases in availability of diagnostic tests among
private for-profit facilities were observed between the first and final survey rounds in Kinshasa (82.1, 94.0%, p < 0.05),
Nigeria (37.0, 66.0%, p < 0.05), Kenya (52.8, 74.3%, p < 0.001), mainland Tanzania (66.8, 93.5%, p < 0.01), Uganda (47.1,
70.1%, p < 0.001), and Madagascar (14.5, 45.0%, p < 0.01). Blood testing availability remained low over time among
anti-malarial stocking private health facilities in Benin (33.1, 20.7%), and high over time in Zambia (94.4, 87.5%), with
evidence of falls in availability in Katanga (72.7, 55.6%, p < 0.05). Availability among anti-malarial stocking pharmacies
and drug stores—which are the most common source of anti-malarial medicines—was rare in all settings, and highest in Uganda in 2015 (21.5%). Median private sector price of RDT for a child was equal to the price of pre-packaged
quality-assured artemisinin-based combination therapy (QAACT) treatment for a two-year old child in some countries,
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and 1.5–2.5 times higher in others. Median private sector QAACT price for an adult varied from having parity with an
RDT for an adult to being up to 2 times more expensive. The exception was in both Kinshasa and Katanga, where the
median price of QAACT was less expensive than RDTs.
Conclusions: Significant strides have been made in the availability of testing, mainly through the widespread distribution of RDT, and especially in public health facilities. Significant barriers to universal coverage of diagnostic testing
can be attributed to very low availability in the private sector, particularly among pharmacies and drug stores, which
are responsible for most anti-malarial distribution. Where tests are available, price may serve as a barrier to uptake,
particularly for young children. Several initiatives that have introduced RDT into the private sector can be modified
and expanded as a means to close this gap in malaria testing availability and promote universal diagnosis.
Keywords: Malaria test, Rapid diagnostic test, Microscopy, Price, Market share, Availability, sub-Saharan Africa

Background
Since 2010, the World Health Organization (WHO)
guidelines have recommended that all cases of suspected
malaria should receive a confirmatory test with microscopy or a rapid diagnostic test (RDT) to confirm the
diagnosis [1] and since 2012, this recommendation has
been promoted through WHO’s ‘test, treat, and track’
strategy. Although malaria remains a public health concern, resulting in over 300,000 deaths in children under
five [1], recent control efforts have significantly reduced
the disease burden, especially in high transmission areas
of Africa [2]. The decreased prevalence of malaria has
emphasized the need to move away from presumptive
treatment. This, together with the introduction of RDT
technology, has allowed for malaria diagnosis to take
place in remote and resource-poor settings [3], and has
influenced the shift in policy to confirmatory testing [4].
Confirmatory testing of suspected cases of malaria with
microscopy or RDT prior to treatment has the potential
to enhance accurate diagnosis, and improve treatment
of malaria and other febrile illnesses and reduce wastage
of anti-malarial drugs [5]. Confirmatory testing has been
shown to decrease the inappropriate use of the effective
artemisinin-based combination therapy (ACT), which is
the first-line treatment for the majority of countries in
sub-Saharan Africa (SSA) [1]. It is thought that reducing
inappropriate use of this treatment will impede the rate
of resistance to ACT and decrease how much governments will need to spend on purchasing and supplying
these medicines to health facilities [6–9].
National guidelines across SSA stipulate confirmatory
testing prior to treatment, and national malaria control
programmes and their partners have implemented strategies to improve access to testing through the scale up of
RDT, particularly in the public sector [10]. Despite this,
current evidence from population-based surveys suggests that confirmatory testing rates with microscopy or
RDT remain low. According to recent household surveys
conducted between 2013 and 2015 in SSA, the proportion of children under five with recent fever who received

a malaria test was just 31% (Interquartile range [IQR]
19–40%) [1].
Current and comprehensive information about availability, price and the relative sale or distribution of RDT
versus microscopy in the public and private sectors for
diagnostic testing in SSA is needed. This will help to
inform and monitor strategies to increase the proportion
of suspected malaria cases receiving a confirmatory test.
However, this information has to date not been available. Most studies that evaluate accessibility to malaria
diagnostic testing tend to be small in scale, not nationally representative, focus on either the public or private
sector only, or observe only one time point [11–15]. A
more recent multi-country ACTwatch assessment of
malaria diagnostic testing availability across the public and private sectors, published in 2015, focused solely
on RDT availability in eight SSA countries during 2011
[16]. Other data on availability, price and market share of
microscopy and RDT have been made available through
multiple survey rounds, but data have not yet been collated across countries and presented overtime for key
indicators.
ACTwatch was launched in 2008 by Population Services International (PSI), with support from the Bill
and Melinda Gates Foundation, UNITAID and the UK
Department for International Development (DFID)
and was implemented in collaboration with the London
School of Hygiene and Tropical Medicine. The goal of the
project was to generate timely, relevant, and high quality
evidence about anti-malarial markets for policy makers,
donors, and implementing organizations. The aim of this
paper is to address gaps in information concerning public and private sector availability, price and market share
of microscopy and RDTs across eight malaria-endemic
countries in SSA (Benin, the Democratic Republic of the
Congo [DRC], Nigeria, Kenya, mainland Tanzania (subsequently referred to as Tanzania), Uganda, Madagascar
and Zambia). Data collected by the ACTwatch project
over multiple time points between 2009/11 and 2014/15
are presented to describe significant trends in availability,
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and to summarize private sector price and relative market share of RDT and microscopy for the public and
private sector. Policy regarding private sector permission to use RDT varies by country and outlet type (see
Table 1) and data are also presented to describe differences between private sector outlet types. The results will
be useful to inform, monitor, and evaluate policies and
strategies designed to improve access and use of malaria
diagnostic testing.

Methods
Design and sampling

ACTwatch outlet surveys are nationally-representative
(with the exception of the sub-national surveys in the
DRC), cross-sectional quantitative surveys conducted
among a sample of outlets stocking anti-malarial medicines and diagnostics. Detailed ACTwatch project and
methodological information have been published elsewhere [17, 18].
All categories of outlets with the potential to stock
anti-malarials in both the public and private sector were
included in the study. Potential outlets include public and
private outlets that may be likely to stock anti-malarial
medicines or diagnostics according to each country context. In the public sector, this included government and
non-government not-for-profit health facilities (hospitals, health centres, clinics, and health posts) and community health workers. Outlets sampled in the private
sector included private for-profit health facilities (hospitals, health centres, and clinics), pharmacies, drug stores
(registered/regulated and unregistered/unregulated),

general retailers selling fast-moving consumer goods and
itinerant drug vendors (mobile vendors without a fixed
service delivery point).
Lists of all potentially eligible outlets were not routinely
available and therefore a cluster sampling approach with
an outlet census was used to identify outlets for inclusion.
Clusters were administrative units ideally with a size of
10,000–15,000 inhabitants, and were selected using probability proportional to population size sampling. Within
each selected cluster all outlets with the potential to provide anti-malarials to consumers were screened for eligibility. Outlets were eligible for an anti-malarial product
audit if they had one or more anti-malarials in stock on
the day of the survey or/and malaria diagnostic testing.
Boundaries for the outlet census were typically
extended to higher administrative units to cover a larger
area for the census of public health facilities and pharmacies, in order to over-sample these relatively uncommon
but important outlet types.
Each survey was stratified to deliver estimates for relevant research domains: all countries had urban and rural
stratification, with the exception of Nigeria for which
six geopolitical zones were used as research domains.
Each study round was powered to detect a minimum of
a 20-percentage point change in availability of qualityassured ACT (QAACT) among anti-malarial stocking outlets between each round and between domains
in a given round at the 5% significance level with 80%
power. The number of study clusters was calculated for
each research domain based on the required number of
anti-malarial stocking outlets and assumptions about

Table 1 National policy regarding permission to administer RDT across private sector outlet types
Private for-profit health facilities Pharmacies and drug stores
West and Central Africa
Benin

Only accredited private health facilities are permitted to administer testing

DRC

Permitted to administer RDT

Pharmacies with a licensed pharmacist are permitted to administer RDT. Other drug
stores are not allowed to administer RDT

Nigeria

Permitted to administer RDT

Drug stores, or Patient Propriety Medicines Vendors (PPMV) as they are called in Nigeria,
were granted approval to administer RDT in 2015 at national level. Approval at subnational level varies across states. Pharmacies are allowed to administer RDT within
approved project pilots as of 2014

Kenya

Permitted to administer RDT

Not permitted to administer RDT. Pharmacies are allowed to administer RDT within
approved project pilots as of 2014

Tanzania

Permitted to administer RDT

Accredited drug dispensing outlets (ADDOs) are allowed to administer RDT within
approved project pilots. Policy granting permission to administer RDT for ADDOs is
under review

Uganda

Permitted to administer RDT

Drug stores and pharmacies are allowed to administer RDT within approved project
pilots. Policy granting permission to administer RDT is under review

Madagascar

Permitted to administer RDT

Pharmacies and drug stores permitted to administer RDT nationwide since 2014

Zambia

Permitted to administer RDT

Not permitted to administer RDT

East Africa

Southern Africa
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the number of anti-malarial stocking outlets per cluster.
Sample size requirements for follow-up surveys were calculated using information from previous survey rounds
including anti-malarial and QAACT availability, outlet
density per cluster, and design effect.
Data collection periods varied by country and over time
but were typically implemented during the peak malaria
transmission season for each country and lasted between
6 weeks and 2 months. Efforts were made to ensure surveys were implemented over similar time points across
the survey rounds.
Training and fieldwork

Interviewer training consisted of standardized classroom presentations and exercises as well as a field exercise. Exams administered during training were used to
select data collectors, supervisors, and quality-controllers. Additional training was provided for supervisors
and quality-controllers and focused on field monitoring,
verification visits, and census procedures. Data collection
teams were provided with a list of selected clusters and
official maps that illustrated their administrative boundaries. In each selected cluster, data collectors conducted a
full enumeration of all outlets that had the potential to
provide anti-malarials and/or malaria blood testing. This
included enumeration of outlets with a physical location,
as well as identification of community health workers and
itinerant drug vendors using local informants and snowball sampling. The primary provider/owner of each outlet was invited to participate in the study, and screening
questions were administered to assess anti-malarial or/
and malaria diagnostic availability. Interviews were conducted in local language using questionnaires that were
translated from English to the local language using a forwards and backwards blind translation. Quality control
measures implemented during data collection included
questionnaire review by supervisors, and spot checks by
quality controllers on 10–20% of all outlets.
Measures

The outlet survey questionnaire included an audit of all
available RDT. Providers were asked to show the interviewer all RDT that were available in the outlet. A product audit sheet captured information for each unique
RDT in the outlet, including brand name, manufacturer,
and country of manufacture. Providers were asked to
report the retail and wholesale price for each RDT as
well as the number of RDT distributed/administered to
individual customers in the previous week. Providers
additionally reported on malaria microscopy services
including availability, price, and number of individuals
tested for malaria by microscopy in the previous week
(see Additional file 1 for a sample of the ACTwatch
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questionnaire). All surveys were paper-based with the
exception of Madagascar (2015) and Uganda (2015),
where data were collected using Android phones and
forms created using DroidDB (© SYWARE, Inc., Cambridge, MA, USA).
Protection of human subjects

The outlet survey protocols received ethical approval
from national ethical approval boards within each country. Provider interviews and product audits were completed only after administration of a standard informed
consent form and provider consent to participate in
the study. Providers had the option to end the interview at any point during the study. Standard measures
were employed to maintain provider confidentiality and
anonymity.
Data analysis

Double data entry was conducted using Microsoft Access
(Microsoft Corporation, Redmond, WA, USA) with builtin range and consistency checks. Data were analyzed
across survey rounds using Stata (StataCorp College Station, TX).
Standard indicators were constructed according to definitions applied across the ACTwatch project which have
been described elsewhere [17, 18]. Availability of RDT
was defined as presence of one or more RDT at the outlet at the time of the survey. Availability of microscopy
was defined as provider report of availability of malaria
microscopy testing services. Functionality of the microscope and availability of slides and Giemsa stain were
not confirmed. Availability of malaria testing was calculated among all screened outlets for public health facilities, and among anti-malarial stockists for all other outlet
types. An anti-malarial stockist was defined as an outlet
with one or more anti-malarials in stock on the day of the
survey, or reportedly in stock within the past 3 months.
Significant differences in test availability levels between
years in each country were estimated using logistic
regression, with a binary dependent variable for availability of testing at the outlet level, and a dummy independent variable for year.
The private sector price of a malaria test using microscopy or RDT was assessed through provider reports of
consumer prices for the last survey round. Price data presented were collected in local currencies and converted
to United States dollars using official exchange rates for
the period of data collection. Providers were asked to
report the total cost of testing to a customer including
any consultation or service fees. Median private sector
price for RDTs was calculated and reported with the IQR
as a measure of dispersion. Median estimates were not
reported on in cases of low sample size, specifically where
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the N contributing to a median price estimate was below
20. Price of testing was compared with median price
for pre-packaged treatment with a first-line QAACT.
In countries with two first-line ACT, the most common
was selected for the median price comparison. The most
common pre-packaged QAACT treatment for an adult
was artemether-lumefantrine (AL) in all countries except
Madagascar and Kinshasa (DRC) and Katanga (DRC)
where it was artesunate–amodiaquine (ASAQ). The
price of testing for an adult was compared to the price
of pre-packaged therapy for a 60 kg adult (e.g. AL 20/120
package size of 24 tablets). The price of testing for a child
under five was compared to the price of pre-packaged
therapy for a 10 kg child (e.g. AL 20/120 package size of
6 tablets).
QAACT were ACT products meeting one of three
criteria: (1) the product had WHO pre-qualified status;
(2) the product was in compliance with the Global Fund
quality assurance policy and appeared on the Global
Fund list of approved products for procurement; or (3)
the product was granted regulatory approval by the European Medicines Agency.
Provider reports on the number of people tested using
RDT or malaria microscopy during the week preceding the survey were used to calculate the relative market
share for the public and private sector and for the type
of test (RDT and microscopy). The relative market share
for a sector or test type is the number of tests that were
reportedly performed on each customer during the week
preceding the survey for the sector/test type as a percentage of all tests performed across sectors.
Outlets were grouped into three main categories: (1)
public health facilities consisting of government and private not-for-profit facilities; (2) private for-profit health
facilities; and (3) pharmacies and drug stores. Results are
presented separately for private for-profit health facilities and pharmacies/drug stores given the differences in
testing policy for these outlet types (Table 1). Additional
file 2 includes findings for other outlet types including
community health workers, general retailers, and itinerant drug vendors, given the general low availability of
malaria blood testing among these outlet types.
Sampling weights were calculated as the inverse of the
probability of cluster selection. All point estimates were
weighted using survey settings and all standard errors
calculated taking account of the clustered and stratified
sampling strategy with Stata survey commands.

Results
A total of 198,836 outlets were screened to assess availability of anti-malarials and blood testing across the
eight countries and 28 survey rounds between 2009/11
and 2014/15. Anti-malarials were available on the day
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of the survey or within the previous 3 months among a
total of 52,312 outlets. In total, 11,981 RDT were audited
(Table 2).
Malaria blood testing availability

The availability of malaria blood testing (RDT or
microscopy) among all screened public health facilities
increased significantly between 2009/11 and 2014/15
in Benin (36.2, 85.4%, p < 0.001), Kenya (53.8, 93.0%,

Table 2 Results of the outlet census and RDT audit
by country and survey year
Country

Year

Screened (N Anti-malarial
of outlets)
stockista (N
of outlets)

RDT products
auditedb (N
of products)

West and Central Africa
Benin

2011

2891

1413

96

2014

4332

1939

239

Kinshasa
(DRC)

2009

2368

777

n/a

2013

3364

977

79

2015

1168

1078

267

Katanga
(DRC)

2013

2270

785

140

2015

1052

1027

435

Nigeria

2009

5456

2160

n/a

2011

7938

1548

44

2013

5148

1784

448

2015

13,480

3568

489

2010

13,897

2554

75

2011

11,383

2084

144

2014

12,676

2405

654

2010

3120

650

28

2011

3702

798

41
504

East Africa
Kenya

Tanzania

Uganda

2014

4724

2138

2010

11,153

2499

180

2011

16,207

3226

843

2013

7932

3472

1573

2015

9438

4598

2267

Southern Africa
Madagascar

Zambia

2010

6769

2593

n/a

2011

10,046

2790

722

2013

10,149

1906

1087

2015

13,481

1203

699

2009

3378

459

n/a

2011

5436

860

278

2014

5878

1021

649

n/a not applicable, indicates years during which RDT availability was assessed
but an audit of all available RDT was not conducted
a

Outlets with at least one anti-malarial in stock on the day of the survey or
within the past 3 months (completed interview)

b

Represents the number of RDT products that were audited at an outlet during
each survey round
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p < 0.001), Tanzania (46.9, 89.9%, p < 0.001), Nigeria
(28.5, 86.2%, p < 0.001), Katanga (76.0, 88.2%, p < 0.05),
and Uganda (38.9, 95.6%, p < 0.001). Testing availability
was not significantly different between survey rounds in
Kinshasa (87.6, 97.6%) and Zambia (87.9, 91.6%). Testing
availability significantly decreased in Madagascar (88.1,
73.1%, p < 0.01) (Fig. 1).
A significant increase in availability of RDT was found
in Benin (30.5, 75.4%, p < 0.001), Kenya (8.7, 62.6%,
p < 0.001), Tanzania (20.8, 76.2%, p < 0.001), Kinshasa
(2.9, 50.4%, p < 0.001), Katanga (47.8, 84.7%, p < 0.001),
Nigeria (8.6, 83.4%, p < 0.001), and Uganda (4.0, 83.6%,
p < 0.001) (Table 3). In Madagascar there was a significant decline in testing availability of RDT (Table 3).
In the anti-malarial stocking private sector, the availability of malaria blood testing (RDT or microscopy)
among the private for-profit sector increased significantly between 2009/11 and 2014/15 in Kinshasa (82.1,
94.0%, p < 0.05), Nigeria (37.0, 66.0%, p < 0.05), Kenya
(52.8, 74.3%, p < 0.001), Tanzania (66.8, 93.5%, p < 0.01),
Uganda (47.1, 70.1%, p < 0.001) and Madagascar (14.5,
45.0%, p < 0.01). Blood testing availability did not change
significantly over time in Benin (33.1, 20.7%). and Zambia (94.4, 87.5%). Significant declines were observed in
Katanga (72.7, 55.6%, p < 0.05) (Fig. 2).

In comparison with private for-profit facilities, the
availability of malaria blood testing among anti-malarial
stocking pharmacies and drug stores was lower across
all countries. During the most recent survey round, testing availability among anti-malarial stocking pharmacies
and drug stores ranged from 0.1% in Benin to 21.5% in
Uganda. Among pharmacies and drug stores, a significant
increase in availability was observed between 2009/11
and 2014/15 in Nigeria (1.1, 7.1%, p < 0.001), Kenya (10.7,
17.0%, p < 0.05), Tanzania (0.4, 6.2%, p < 0.001), Uganda
(4.5, 21.5%, p < 0.001), and Madagascar (0.4, 12.4%,
p < 0.001) (Fig. 2).
Among private for-profit facilities, a significant
increase in availability of RDT was observed in Nigeria (11.0, 42.4%, p < 0.05), Kenya (6.7, 29.3% p < 0.001),
Uganda (9.7, 47.7%, p < 0.001), and Madagascar (12.5,
43.8%, p < 0.01). In Kenya, significant increases in
microscopy availability were observed (48.5, 61.1%,
p < 0.05). In Katanga, malaria microscopy availability showed significant declines (49.2, 23.3%, p < 0.01)
(Table 4). Among pharmacies and drugs stores, a significant increase in availability of RDT was observed in
Nigeria (0.5, 7.0%, p < 0.05), Kenya (2.2, 12.8% p < 0.001),
Tanzania (0.4, 5.7%, p < 0.01), Uganda (2.2, 20.7%,
p < 0.001), and Madagascar (0.45, 12.4%, p < 0.001)

100

PERCENT OF ALL SCREENED OUTLETS

90
80
70
60
50
40
30
20
10
0

2011 2014 2009 2013 2015 2013 2015 2009 2011 2013 2015 2010 2011 2014 2010 2011 2014 2010 2011 2013 2015 2010 2011 2013 2015 2009 2011 2014
Benin

DRC, Kinshasa

DRC,
Katanga

Nigeria

Kenya

Tanzania

West & Central Africa

Uganda

Madagascar

East Africa

Zambia

Southern Africa

Notes: Tests for significance differences in malaria testing availability between first and final years of the survey rounds
Benin
***

DRC,
Kinshasa
ns

Abbreviations: ns: Not significant;

DRC,
Katanga
*
* p<0.05;

Nigeria

Kenya

Tanzania

Uganda

Madagascar

Zambia

***

***

***

***

**

ns

** p<0.01;

*** p<0.001

Fig. 1 Availability of malaria blood testing among all screened public health facilities (Public health facilities are inclusive of government and nongovernment not-for-profit hospitals, clinics, health centers and health posts), 2009/11–2014/15
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Table 3 Percentage of all screened public health facilitiesa
with RDT and microscopy available on the day of the survey, over time
n

% Outlets stocking
RDT (95% CI)

% Outlets
with microscopy
available (95% CI)

West and Central Africa
Benin
  2011

257

30.5 (21.3, 41.7)

  2014

263

75.4 (64.6, 83.8)***

8.8 (5.0, 15.1)
17.8 (11.4, 26.8)*

Kinshasa (DRC)
  2009

27

2.9 (0.5, 14.2)

86.2 (66.1, 95.3)

  2013

89

23.5 (13.3, 38.1)

89.3 (81.0, 94.3)

  2015

277

50.4 (39.9, 61.0)***

91.2 (84.5, 95.1)

47.8 (34.0, 61.9)

47.6 (36.3, 59.1)

84.7 (77.2, 90.0)***

30.8 (24.2, 38,2)*

Katanga (DRC)
  2013

97

  2015

284

Nigeria
  2009

249

8.6 (1.8, 32.9)

28.5 (10.7, 56.9)

  2011

109

14.9 (7.5, 27.7)

24.7 (14.8, 38.4)

  2013

711

43.0 (29.6, 57.6)

12.6 (5.8, 25.4)

  2015

210

83.4 (72.7, 91.0)***

27.8 (15.9, 44.2)***

East Africa
Kenya
  2010

443

8.7 (4.6, 16.0)

49.8 (43.2, 56.4)

  2011

474

18.5 (9.7, 32.4)

44.6 (36.1, 53.5)

  2014

528

62.6 (55.6, 69.0)***

66.4 (62.2, 70.4)***

Tanzania
  2010

87

20.8 (10.1, 38.0)

28.1 (20.0, 38.0)

  2011

64

38.6 (23.5, 56.3)

25.0 (15.4, 37.8)

  2014

336

76.2 (69.4, 81.9)***

32.3 (26.2, 39.0)

Uganda
  2010

811

4.0 (1.7, 9.2)

36.2 (28.8, 44.3)

  2011

718

51.2 (44.7, 57.6)

47.8 (41.5, 54.2)

  2013

728

79.5 (71.8, 85.5)

41.4 (36.1, 47.0)

  2015

334

83.6 (75.4, 89.5)***

59.0 (51.1, 66.6)***

Southern Africa
Madagascar
  2010

524

87.4 (81.3, 91.6)

3.7 (2.1, 6.3)

  2011

669

89.7 (84.9, 93.1)

5.7 (4.6, 7.2)

  2013

620

87.4 (82.7, 91.0)

14.7 (7.7, 26.2)

  2015

273

72.0 (62.0, 80.3)**

  2009

178

85.7 (70.4, 93.8)

40.6 (30.5, 51.6)

  2011

294

68.4 (55.4, 79.0)

35.8 (24.9, 48.5)

  2014

498

89.4 (83.8, 93.2)

22.8 (14.3, 34.3)*

3.6 (2.3, 5.5)

Zambia

a

Inclusive of government and non-government not-for-profit hospitals, clinics,
health centers and health posts
CI Confidence Interval
* p < 0.05; ** p < 0.01; *** p < 0.001, in reference to baseline year

(Table 4). Microscopy was rarely available among pharmacies and drug stores in all countries with the exception of Kenya (6.1% in 2014) (Table 4).
In some study countries, community health workers, general retailers, and itinerant drug vendors stocking anti-malarials were also stocking RDT. Among
anti-malarial stocking community health workers, RDT
availability was 58.2% during the most recent survey
round in Uganda, 72.8% in Madagascar and 83.2% in
Zambia. Availability among general retailers and itinerant drug vendors was generally very low (<5%) with the
exception of 8.5% observed during the most recent survey in Tanzania (Additional file 2).
Private sector price of malaria blood testing relative
to treatment

The median private sector price of the most common
pre-packaged QAACT treatment for an adult was 2 times
more expensive than the median price of adult RDT testing in Tanzania, Uganda, and Zambia, and 1.25 more
expensive in Nigeria. QAACT and RDT testing were the
same price in Kenya and Madagascar. In both Kinshasa
and Katanga, the median price of QAACT ($0.00 and
$0.55, respective) was less expensive than RDT testing
(both $1.10). The low price of adult QAACT in Kinshasa
is attributed to low availability of products (N = 40),
which were part of small scale subsidy initiatives.
Malaria microscopy was more expensive than QAACT
for adults in Benin (1.9 times more expensive), Katanga
(2 times more expensive), and Kinshasa (where median
price of treatment was $0.00), Nigeria (1.2 times more
expensive), and Madagascar (8.3 times more expensive),
and was the same price as treatment in Kenya. QAACT
was more expensive than microscopy in Tanzania (2
times more expensive) and Uganda (1.7 times more
expensive) (Fig. 3).
The median private sector price of RDT testing for a
child was higher than the price of pre-packaged QAACT
treatment for a 2-year old child in Katanga (2.5 times
more expensive), Nigeria (1.4 times more expensive),
Kenya (2 times more expensive), Uganda (2.1 times more
expensive), and Zambia (1.5 times more expensive). The
prices of treatment and of RDT for a child were the same
in both Tanzania and Madagascar. Malaria microscopy
for a child was also more expensive than pre-packaged
pediatric treatment in Benin (4.9 times more expensive), Katanga (3.3 times more expensive), Nigeria (4.2
times more expensive), Kenya (2 times more expensive),
Uganda (2.1 times more expensive), and Madagascar
(8.3 times more expensive). The prices of QAACT and of
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Fig. 2 Availability of malaria blood testing among the anti-malarial stocking private sector, 2009/11–2014/15

microscopy for a child were the same in Tanzania (Fig. 4).
In Kinshasa, the median price of prepackaged QAACT
for a 2-year-old child was $0.00, meaning that median
price for both RDT and microscopy was higher than for
treatment here. The low price of QAACT for a 2-yearold child in Kinshasa is attributed to low availability of
products (N = 13), which were part of small scale subsidy
initiatives.
Private sector prices for quality-assured pre-packaged
ACT treatment and testing disaggregated by outlet type
(private facility, pharmacy/drug store) are provided in
Additional file 3.
Malaria blood testing market share

At the time of the most recent survey round, the majority of malaria testing was performed in the public sector
in Zambia (90.9%), Benin (90.3%), Madagascar (84.5%),
Tanzania (73.5%), Uganda (71.8%), Nigeria (68.4%),
Kenya (53.2%), and the DRC, where the public sector was
responsible for 74.3% of tests performed in Katanga and
51.9% in Kinshasa. The majority of malaria blood testing was performed with RDT in Zambia (89.9%), Benin
(76.5%), Madagascar (96.5%), Tanzania (63.5%), Uganda
(70.8%), Nigeria (78.7%), and Katanga (81.9%). Microscopy performed by both the public and private sectors
accounted for the majority of malaria testing in Kenya
(75.4% inclusive of 37.3% public and 38.1% private) and

Kinshasa (63.7% inclusive of 26.9% public and 36.8% private) (Fig. 5).

Discussion
The results from this study show that significant strides
have been made in improving availability of malaria testing, especially in public health facilities, where more than
80% of facilities stocked any test across most countries
during the last survey round. However, population based
evidence suggests that testing uptake remains low, with
only about one-third of children under five with recent
fever receiving a malaria test [19]. The findings from
this survey suggest that this may be attributed to a lack
of private sector availability of testing and price barriers,
particularly in pharmacies and drugs stores, where most
patients seek treatment in SSA.
Limitations

The main strength of this paper is that data are presented
at a national level, with the exception of the DRC where
only Katanga and Kinshasa provinces were surveyed partially due to poor infrastructure that limited travel, and
to insecurity in other regions of the country. In addition,
this study assessed availability, price, and market share in
both the public and private sector, providing a complete
picture of the malaria testing market. However, several
limitations exist. Information on pricing was obtained
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Table 4 Percentage of anti-malarial-stocking private sector outlets with malaria RDT and microscopy available on the
day of the survey over time
Private for-profit health facilitiesa
N

Pharmacies and drug stores

% Outlets stocking
RDT (95% CI)

% Outlets with
microscopy (95% CI)

N

% Outlets stocking
RDT (95% CI)

% Outlets with
microscopy (95% CI)

West and Central Africa
Benin
  2011

134

11.2 (2.4, 38.9)

22.5 (14.4, 33.4)

221

2.2 (9.8, 5.1)

0.0

  2014

139

11.6 (5.2, 23.8)

10.5 (4.0, 24.6)

192

0.1 (< 0.1, 0.4)***

0.1 (< 0.1, 0.4)

Kinshasa (DRC)
  2009

71

5.1 (1.9, 13.0)

81.5 (72.0, 88.2)

661

0.1 (0.0, 1.0)

0.9 (0.4, 2.0)

  2013

200

18.3 (13.2, 25.0)

89.3 (84.2, 92.8)

693

0.4 (0.1, 2.3)

0.0

  2015

176

31.1 (21.8, 42.2)

88.7 (83.2 92.5)

612

1.3 (0.5, 3.2)

0.1 (< 0.1, 1.9)

  2013

134

45.4 (33.4, 58.0)

49.2 (35.2, 63.3)

529

5.4 (3.7, 7.7)

2.2 (1.0, 4.8)

  2015

141

45.9 (36.5, 55.5)

23.3 (15.6, 33,4)**

565

9.4 (5.9, 14.6)

0.8 (0.4, 1.8)

  2009

367

11.0 (2.7, 36.0)

36.1 (29.4, 43.4)

1360

0.5 (0.1, 1.9)

0.6 (0.2, 1.8)

  2011

93

8.6 (3.3, 20.6)

33.2 (19.5, 50.4)

1206

0.9 (0.3, 2.6)

0.2 (< 0.1, 0.9)

  2013

78

46.9 (30.3, 64.2)

24.0 (12.0, 42.2)

885

6.9 (4.3, 11.0)

0.2 (0.1, 1.1)

  2015

240

42.4 (29.3, 56.7)*

41.9 (18.3, 70.0)

2956

7.0 (5.2, 9.4) ***

<0.1 (< 0.1, 0.3)*

  2010

269

6.7 (3.2, 13.6)

48.5 (37.7, 59.4)

655

2.2 (0.8, 6.0)

8.8 (5.8, 13.0)

  2011

280

6.7 (3.7, 11.8)

40.2 (30.4, 50.8)

744

3.1 (1.8, 5.2)

7.6 (5.1, 11.2)

  2014

375

61.1 (56.7, 65.4)*

1045

Katanga (DRC)

Nigeria

East Africa
Kenya

29.3 (25.7, 33.0)***

12.8 (11.0, 14.9)**

6.1 (4.8, 7.8)

Tanzania
  2010

10

8.8 (1.0, 49.1)

58.0 (27.0, 83.8)

455

0.4 (0.1, 1.5)

<0.1 (< 0.1, 0.2)

  2011

25

3.4 (0.6, 17.8)

61.4 (31.6, 84.6)

673

1.0 (0.3, 3.3)

1.4 (0.7, 3.1)

  2014

172

47.7 (40.1, 55.5)

83.1 (75.6, 88.6)

1599

5.7 (3.9, 8.1)***

0.7 (0.3, 1.8)**

Uganda
  2010

394

9.7 (6.6, 14.0)

41.3 (36.3, 46.6)

1220

2.2 (1.2, 3.8)

2.6 (1.2, 4.8)

  2011

811

20.3 (15.7, 25.8)

43.5 (39.2, 47.8)

1544

5.1 (3.6, 7.2)

2.5 (1.4, 4.6)

  2013

394

31.4 (25.9, 37.4)

46.6 (37.6, 55.8)

1512

11.2 (8.4, 14.8)

2.4 (1.4, 4.1)

  2015

966

47.7 (41.7, 53.8)***

41.1 (34.3, 48.1)

2381

20.7 (17.8, 23.9)***

1.1 (0.6, 2.3)

Southern Africa
Madagascar
  2010

71

12.5 (6.5, 22.9)

4.3 (2.1, 8.5)

324

0.4 (0.1, 1.1)

0.1 (< 0.1, 0.3)

  2011

47

7.7 (3.5, 15.9)

3.6 (1.5, 8.4)

461

2.4 (1.2, 4.6)

0.0

  2013

94

45.9 (32.9, 59.5)

9.7 (4.4, 20.4)

529

1.7 (1.0, 3.0)

0.7 (0.1, 5.0)

  2015

182

43.8 (28.0, 60.9)**

3.1 (1.6, 5.7)

271

12.4 (6.5, 22.3)***

0.0

Zambia
  2009

33

78.3 (58.0, 90.5)

74.4 (57.8, 86.1)

189

4.2 (0.9, 17.1)

3.1 (0.4, 20.2)

  2011

49

43.8 (23.6, 66.2)

86.9 (73.1, 94.2)

362

12.7 (4.3, 32.2)

0.1 (< 0.1, 0.6)

  2014

22

68.1 (45.6, 84.4)

72.2 (42.0, 90.3)

354

14.3 (6.5, 28.7)

0.4 (0.1, 0.9)

a

Private for-profit health facilities (hospitals, clinics and health centres) and pharmacies or drug stores with anti-malarials in stock on the day of the survey or within
the previous 3 months
* p < 0.05 ** p < 0.01 *** p < 0.001, in reference to baseline year

by asking the provider how much they would charge
for a test, which may have exposed the data to respondent bias as providers may state a price they consider

more favorable to the interviewers. Another limitation
is that the quality of the RDT or functionality of microscopic tests stocked was not assessed, nor was expiry
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Fig. 4 Median private sector price for malaria testing for a child and quality-assured pediatric ACT treatment
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Fig. 5 Malaria testing market share, by test type and across sectors

information on stocked RDT collected. In addition, while
tests may have been available at an outlet, the length of
waiting time for the results was not assessed, though one
would expect this to be longer for microscopy than for
RDTs. Other limitations specific to the ACTwatch methodology are described in more detail elsewhere [20].
Public health facilities

Increases in testing availability were observed among
public health facilities in several countries. At least nine
in ten public sector facilities had malaria testing available in Kinshasa (DRC), Kenya, Tanzania, Uganda, and
Zambia, and availability was greater than 85% in Benin
and Katanga (DRC). Large increases in availability over
time were observed across most countries, and this was
most striking in Benin and Tanzania between the last two
survey rounds, where availability increased by almost
fifty percentage points. Statistically significant differences were found between the first and final surveys for
all country contexts, with the exception of Kinshasa and
Zambia. These increases were largely achieved through
the extensive deployment of RDT. Market share data,
presented for the last survey round, also illustrated that
the majority of confirmatory tests (up to 90%) were being
carried out in public health facilities, exemplifying the
importance of this sector as a source of confirmatory
testing. In addition, across country contexts, the most
common type of test carried out in public health facilities was RDT, with some exceptions noted in Kenya and
Kinshasa where microscopy was more commonly administered and available.

These findings reflect policies of confirmatory diagnosis that many African countries have adopted since WHO
changed its malaria treatment policy to ‘test, treat, and
track.’ Several countries have implemented programmes
aimed at expanding access to and use of diagnostic testing
among public health facilities, largely focusing on RDT
given evidence that these can be effectively performed
even at lower levels of the health system [21]. The findings presented here are commensurate with public sector
surveillance data from the region, indicating that the proportion of suspected malaria cases receiving a confirmatory test in the public sector increased from 40% in 2010
to 76% in 2015 [1]. Again this is attributed to an increase
in the use of RDT, which accounted for 74% of diagnostic
testing among suspected cases in 2015 [1]. This trend of
increased confirmatory testing among public health facilities is also evident in the results of household surveys,
where the proportion of febrile children who received a
malaria diagnostic test in the public sector rose from a
median of 29% in 2010 (IQR: 19–46%) to a median of 51%
in 2015 (IQR: 35–60%) [1]. Similarly, distribution of RDT
from national malaria control programmes in SSA to
supply the public sector has also increased over the years,
and a total of 179 million were distributed to the public
sector in 2015 [1].
Despite these improvements over time among public
health facilities, the findings from the last survey round
demonstrate that gaps persist and 100% coverage of confirmatory diagnosis has not yet been achieved. In Madagascar, only three-quarters of public health facilities had
testing available, reflecting a decline in recent years and
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a significant reduction since the baseline survey. Stockouts are known to be a common problem facing the public health sector, and this has been demonstrated with
inconsistent supplies of ACT [22]. In Madagascar, the
reduction in availability of RDT among public health
facilities may be explained by a delay in funding, with
orders of RDTs only arriving in country in July 2015 after
several months of stock-outs. Indeed, several challenges
have been reported with maintaining constant public
sector supply including the lack of technical capacity,
archaic procurement methods, and cumbersome tendering processes [23]. Investments to strengthen both the
supply system and the health information system, using
systems such as the District Health Information Software
(DHIS2), will assist in tracking RDT availability and lend
to a more streamlined, demand driven, and accountable
procurement and supply chain system [24].
Private sector

In contrast to the public sector, there has been very little progress in testing scale up in the anti-malarial stocking private sector, particularly among pharmacies and
drug stores—which are the most common source of
anti-malarial medicines [18]. The percentage of outlets
stocking any test in pharmacies and drug stores remained
negligible across most country contexts, and was highest in Uganda in 2015 where 21% of pharmacies/drugs
stores had a test in stock. Availability in the private sector was somewhat higher among private for-profit facilities, where modest improvements in the percentage of
outlets stocking any test were observed, driven by a rise
in RDT distribution. The findings from the outlet survey mirror evidence from population-based surveys in
SSA that illustrate how the proportion of febrile children who received a malaria diagnostic test was greater if
they sought care in the public sector (median: 51%, IQR:
35–60%) than in the formal private sector (median: 40%,
IQR: 28–57%) or in the informal private sector (median:
9%, IQR: 4–12%) [1].
The low availability of malaria tests in pharmacies and
drug stores is a key barrier to improving universal access
to confirmatory testing since these outlet types are an
important source of malaria treatment. For example, in
Nigeria, over 70% of anti-malarial medicines were distributed through drug stores [25], known as PPMVs, yet
less than 10% of these outlets had malaria testing available. Similarly in Tanzania, almost half of the total market share was distributed by pharmacies and drug stores
(ADDOs), but only 6% had confirmatory testing available
[26].
Low private sector availability of malaria testing can
partly be explained by national regulatory frameworks,
which restrict testing in these outlet types. However,
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there is a growing body of evidence that malaria case
management can be well administered among certain
outlet types in the private sector. In Tanzania, a randomized controlled trial to investigate whether the
introduction of RDT among ADDOs improved malaria
case management found that confirmatory diagnosis
increased from 19 to 74% in intervention districts, which
also resulted in improved targeting of ACT to patients
with malaria [12]. Similar positive outcomes have been
demonstrated among Licensed Chemical sellers in
Ghana (private retail sector shops) [27] and drug shops in
Uganda [28]. As such, several strategies have been piloted
in SSA countries to facilitate access to confirmatory testing within pharmacies and drug stores. It has been shown
that these outlets can safely and correctly test for malaria
with appropriate training, supervision, and record keeping [29]. This suggests that the policy in favor of confirmatory testing in pharmacies and drug stores may foster
increased access and appropriate case management of
suspected malaria cases.
However, scaling up malaria testing within the private
sector is not without challenges. While national scale
implementation of RDT in the private sector has not
yet been observed in SSA, this has been implemented in
Cambodia over the past 10 years. A review of Cambodia’s
private sector strategy has pointed to several challenges
in maintaining constant supply of RDT and determining
effective incentives for private providers and patients to
use RDTs and adhere to results [30]. Furthermore, scaleup of RDTs in the private sector is not without major
logistical challenges to ensure appropriate provision and
supply of these commodities and at the same time guarantee safe blood practices and appropriate disposal of
RDT. There may also be inadvertent effects on the use
of antibiotics. Studies from Zanzibar [31] and mainland
Tanzania [32] have shown increased prescription rates
for antibiotics when RDTs were introduced, particularly for negative cases. Scale-up of RDTs in the private
sector would also require time and substantial financial
resources, which some may argue could be better spent
on supervising the public sector. Careful consideration of
future private sector strategies is needed and approaches
should be reviewed according to each country’s context
and regulatory framework.
Prices were only assessed for the last survey round, and
only in the private sector, since tests within the public
sector should be free. In the private sector, the median
private sector price of pre-packaged QAACT treatment
for an adult was either the same price or up to two times
more expensive than the median price of an RDT, with
the exception of Kinshasa and Katanga where the median
price of treatment was less expensive than RDT testing. In contrast, the median private sector price of RDT
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testing for a child was higher than or equal to the price
of pre-packaged QAACT treatment for a 2-year old child
across countries. The median microscopy prices were
generally higher than the price of carrying out an RDT in
both adults and children.
These findings illustrate that where testing is available in the private sector, there appears to be a financial
incentive in many cases for adults to test before treatment. However, among children, the low cost of prepackaged ACT relative to RDT means that there is less
of a financial incentive to test before purchasing ACT for
this age group.
It has been suggested that in order to improve uptake
of testing and therefore targeted treatment, the cost of
testing should be lower than the cost of ACT [9, 33].
One possible way of achieving this is to subsidize RDT
in the private sector along with ACT. Previous empirical
research has provided some support for a combined subsidy. For example, a study in Uganda showed that introducing subsidized RDT in drug shops, alongside training
and community awareness programmes, was able to significantly improve appropriate treatment of malaria over
time. RDT-positive patients were 23 percentage points
more likely to buy ACT (p = .005) and 33.1 percentage
points more likely to buy other antimalarials (p < .001)
than RDT-negative patients[9]. Lessons learned from
pilot studies have shown that such subsidies do increase
uptake of RDT [33, 34], and are most effective when
prices are at a level that will still create sufficient profit
to encourage providers to offer testing as a service, and
manufacturers to continue producing these products [9,
34, 35]. RDT subsidies will need to be supported with
behavior change communication to safeguard the proper
use of the tests by providers [34, 35] and to ensure febrile
patients are encouraged to test prior to treatment.
Achieving high levels of confirmatory testing prior to
treatment and ensuring rational ACT use will require
solutions that include the private sector. As previously
discussed, this may include the introduction of subsidized RDT into certain outlet types in the private sector
such as drug stores that play a role in malaria case management. Indeed, several studies have provided evidence
that acceptance of malaria testing is generally high, with
most patients welcoming the idea of receiving treatment
based on a confirmed diagnosis [36–38]. However, recent
evidence has pointed to several challenges around the
poor communication practices between providers and
patients, and the testing process, including limited interpersonal exchange between providers and patients which
can lead to poor malaria case management [39]. To
overcome this, future strategies may benefit from clear
provider protocols to enable a more effective patient
assessment and discussion on test outcomes, to include
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reasons for carrying out the test, particularly among
RDT-negative patients [38]. There are also inherent challenges when patients test negative for malaria, particularly in the private sector, where providers may not have
the qualifications or experience to know how to correctly
manage the patient [30]. There is also evidence that providers do not always comply with testing guidelines and
may treat patients with anti-malarials despite negative
malaria tests for several reasons, including a mistrust in
the accuracy of the tests [5, 6]. Provider strategies to overcome these challenges could include testing guidelines, as
well as continuous training and monitoring [27, 29, 40]
and the use of SMS messaging to improve both use of
tests and compliance to test guidelines [41]. In addition,
parallel efforts could be implemented such as incentive
schemes, including bundling free ACT medicines with
provider wholesale purchases of subsidized tests, to help
promote provider uptake, distribution and increase profit
margins [34, 42]. Such strategies and approaches may be
adapted and refined according to each country’s context
and regulatory framework(s).

Conclusion
The results from this paper have shown that significant
strides have been made in the availability of testing, especially in public health facilities, most notably due to an
increase in the procurement of RDT. In the public sector,
universal coverage of confirmatory diagnosis has almost
been achieved in many countries and most confirmatory malaria tests are administered through this sector.
However, stock-outs and procurement challenges must
be continually monitored to ensure constant supply and
uptake of RDT. In contrast, persistent gaps still remain
in the private sector, with availability lagging behind the
public sector, especially among pharmacies and drug
stores, where most anti-malarials are distributed. This
may be attributed to national regulations prohibiting the
provision of malaria testing in these outlets, but also to
RDT price barriers, particularly for children, which serve
as a disincentive to test prior to treatment. These issues
have the potential to impact both malaria control efforts
and prospects for elimination, however several private
sector strategies may provide innovative solutions for
maximizing testing services across a range of contexts.
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